A Phase 2 of VIB7734 for the Treatment of Moderate to Severely Active SLE - NCT04925934

Proportion of Participants who achieve BICLA and OGC (oral glucocorticoid) reduction response at Week 48, Proportion of Participants with CLASI-A score ≥ 10 at Baseline (Day 1) who achieve ≥ 50% reduction from Baseline (Day 1) in CLASI-A score at Week 12, Proportion of Participants achieving an SRI-4 response and an OGC dose ≤ 7.5 mg/day and ≤ Baseline (Day 1) dose of prednisone or equivalent at Week 48, (and 2 more...)